Alaunos Therapeutics

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.